Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H31NO4 |
| Molecular Weight | 397.5072 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1OCC
InChI
InChIKey=OMFNSKIUKYOYRG-MOSHPQCFSA-N
InChI=1S/C24H31NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-10,13-16,25H,5-8,11-12H2,1-4H3/b20-13-
Drotaverine, an antispasmodic drug, is a synthetic derivative of the natural isoquinoline alkaloid of Papaver somniferum, papaverine. It inhibits cyclic-3',5'-nucleotide-phophodiesterase (PDE) enzymes with concentration-dependent specificity, in addition, it behaves as a L-type voltage- operated calcium channel (L-VOCC) blocker. Drotaverin also acts as a cytostatic compound for several human tumor cell lines. Drotaverine is an effective medicine to treat spasm or twitches of the smooth muscles in the stomach and heart. It is used to relieve pain caused due to irritable bowel syndrome, headache, menstrual periods, and is also used to relieve cervical spasm during labor.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010-12 |
|
| [Acute intermittent porphyria and oral contraception. Case report]. | 2006-03 |
|
| Pharmacokinetics and bioavailability of drotaverine in humans. | 1996-07-01 |
Patents
Sample Use Guides
The drug is administered for interior use. 1-2 tablets (0.04—0.08 g) 2—3 time a day. In children under 6 0.01—0.02 g 1—2 times a day, in children of 6—12 years old — 0.02 g 1—2 times a day. In children after 12 the adult dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27879007
Drotaverin also acts as a cytostatic compound for several human tumor cell lines and nonmalignant mouse fibroblasts, and EC50 values as low as 3.0 μM were observed in SRB assays for HT-29 human colorectal carcinoma cells.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA03AD02
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
||
|
WHO-ATC |
A03AD02
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
||
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
||
|
NCI_THESAURUS |
C29698
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60161227
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
DROTAVERINE
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
C65489
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
SUB06415MIG
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
98QS4N58TW
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
100000081027
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
2239
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
C005317
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
14009-24-6
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL551978
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
1712095
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
969
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
DB06751
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | |||
|
23684
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
m4773
Created by
admin on Mon Mar 31 18:12:53 GMT 2025 , Edited by admin on Mon Mar 31 18:12:53 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)